Login / Signup

Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!

Arushi KhuranaMatthew John Maurer
Published in: British journal of haematology (2021)
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • phase iii
  • minimally invasive
  • study protocol
  • phase ii
  • clinical trial
  • randomized controlled trial
  • open label
  • placebo controlled